High-risk, recurrent and oligometastatic prostate cancer: recent developments on the role of radiation. Issue 3 (May 2021)

• Record Type: Journal Article
• Authors: Molitoris, Jason K.; Alexander, Gregory S.; Siddiqui, Osman; Cohen, Justin; Mishra, Mark V.; Rana, Zaker
• Is Part Of: Current opinion in oncology. Volume 33:Issue 3(2021)
• Publication Date: 2021-05
• Subjects: brachytherapy -- prostate cancer -- radiotherapy; Oncology -- Periodicals; 616.994
• DOI: 10.1097/CCO.0000000000000720
• Languages: English
• ISSNs: 1040-8746

Abstract

Abstract : Purpose of review: Although a standard of care in the treatment of organ-confined prostate cancer, use of radiation for treatment in the high-risk, metastatic and salvage settings is evolving rapidly. Recent findings: Recent clinical trials have explored the role of increased treatment for high-risk disease with the addition of adjuvant chemotherapy and expanded the role of radiation in settings previously reserved for systemic therapy. Addition of adjuvant chemotherapy for high-risk prostate cancer is controversial and recent evidence is discussed that continues to refine the patient population for further evaluation. Evidence recently published demonstrates that for patients with low burden metastatic disease and those with oligometastatic disease may have a survival benefit with radiation treatment to all sites of known disease. Finally, reirradiation after prior radiotherapy-based treatment offers a potential salvage option for patients with locally recurrent prostate cancer. Summary: As treatment paradigms evolve for prostate cancer, recent evidence continues to demonstrate benefit for the use of local therapy, both in patients with organ-confined disease and, more increasingly, in those with limited metastatic or locally recurrent disease. Further work is needed to identify subgroups of patients who may benefit from available treatment escalation approaches.